Deciphera Pharmaceuticals Inkomsten in het verleden

Verleden criteriumcontroles 0/6

De winst van Deciphera Pharmaceuticals is gedaald met een gemiddeld jaarlijks percentage van -1.8%, terwijl de winst van de Biotechs -industrie jaarlijks groeide met 19%. De inkomsten zijn groeide met een gemiddeld percentage van 42.6% per jaar.

Belangrijke informatie

-1.8%

Groei van de winst

11.9%

Groei van de winst per aandeel

Biotechs Groei van de industrie	17.0%
Inkomstengroei	42.6%
Rendement op eigen vermogen	-60.2%
Nettomarge	-108.9%
Laatste winstupdate	31 Mar 2024

Recente prestatie-updates uit het verleden

Recent updates

Deciphera Pharmaceuticals, Inc.'s (NASDAQ:DCPH) 61% Share Price Surge Not Quite Adding Up

Apr 30

Diving Into Deciphera Pharmaceuticals

Apr 26

We Think Deciphera Pharmaceuticals (NASDAQ:DCPH) Can Afford To Drive Business Growth

Mar 13

We Think Deciphera Pharmaceuticals (NASDAQ:DCPH) Can Afford To Drive Business Growth

Dec 02

Are Investors Undervaluing Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH) By 41%?

Sep 25

Deciphera Pharmaceuticals (NASDAQ:DCPH) Is In A Good Position To Deliver On Growth Plans

Jul 26

Calculating The Intrinsic Value Of Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH)

Jun 22

Lacklustre Performance Is Driving Deciphera Pharmaceuticals, Inc.'s (NASDAQ:DCPH) Low P/S

May 08

We Think Deciphera Pharmaceuticals (NASDAQ:DCPH) Can Afford To Drive Business Growth

Apr 10

We Think Deciphera Pharmaceuticals (NASDAQ:DCPH) Can Afford To Drive Business Growth

Dec 29

Deciphera initiated at buy at Cowen on Qinlock growth, pipeline; sees 68% upside

Aug 29

Deciphera Pharmaceuticals Q2 2022 Earnings Preview

Aug 03

We Think Deciphera Pharmaceuticals (NASDAQ:DCPH) Needs To Drive Business Growth Carefully

Jul 29

Deciphera Pharmaceuticals: Not Too Happy With The Risk-Reward Right Now

Feb 11

Deciphera Pharmaceuticals: The 75% Haircut Doesn't Seem Justified

Nov 22

Deciphera Pharmaceuticals (NASDAQ:DCPH) Is In A Good Position To Deliver On Growth Plans

Aug 26

Deciphera Pharmaceuticals posts data from cancer studies at ASCO21

Jun 04

Companies Like Deciphera Pharmaceuticals (NASDAQ:DCPH) Are In A Position To Invest In Growth

May 10

Opbrengsten en kosten

Hoe Deciphera Pharmaceuticals geld verdient en uitgeeft. Gebaseerd op laatst gerapporteerde winst, op LTM-basis.

Inkomsten en omzetgeschiedenis

NasdaqGS:DCPH Opbrengsten, kosten en inkomsten (USD Millions )
Datum	Inkomsten	Inkomsten	G+A Uitgaven	R&D-uitgaven
31 Mar 24	175	-190	139	0
31 Dec 23	163	-195	136	0
30 Sep 23	151	-194	130	0
30 Jun 23	144	-187	126	0
31 Mar 23	138	-182	123	0
31 Dec 22	134	-179	120	0
30 Sep 22	122	-221	121	0
30 Jun 22	109	-258	127	0
31 Mar 22	100	-286	130	0
31 Dec 21	96	-300	132	0
30 Sep 21	91	-274	129	0
30 Jun 21	84	-258	124	0
31 Mar 21	67	-255	121	0
31 Dec 20	42	-266	114	0
30 Sep 20	23	-271	108	0
30 Jun 20	7	-263	96	0
31 Mar 20	25	-218	76	-36
31 Dec 19	25	-192	66	0
30 Sep 19	25	-157	48	27
30 Jun 19	25	-126	36	48
31 Mar 19	0	-126	29	102
31 Dec 18	0	-100	21	0
30 Sep 18	0	-87	19	71
30 Jun 18	0	-75	17	60
31 Mar 18	0	-64	14	51
31 Dec 17	0	-50	11	40
30 Sep 17	0	-39	9	30
30 Jun 17	0	-33	8	25
31 Mar 17	0	-28	7	22
31 Dec 16	0	-26	6	20

Kwaliteitswinsten: DCPH is momenteel verliesgevend.

Groeiende winstmarge: DCPH is momenteel verliesgevend.

Analyse vrije kasstroom versus winst

Analyse van de winstgroei in het verleden

Winsttrend: DCPH is verliesgevend en de verliezen zijn de afgelopen 5 jaar toegenomen met een snelheid van 1.8% per jaar.

Versnelling van de groei: Het is niet mogelijk om de winstgroei van DCPH over het afgelopen jaar te vergelijken met het gemiddelde over de afgelopen vijf jaar, omdat het bedrijf momenteel verliesgevend is.

Winst versus industrie: DCPH is verlieslatend, waardoor het lastig is om de winstgroei van het afgelopen jaar te vergelijken met die van de Biotechs industrie ( -2.3% ).

Rendement op eigen vermogen

Hoge ROE: DCPH heeft een negatief Return on Equity ( -60.25% ), omdat het momenteel verliesgevend is.

Deciphera Pharmaceuticals Inkomsten in het verleden

Verleden criteriumcontroles 0/6

Belangrijke informatie

Recente prestatie-updates uit het verleden

First quarter 2024 earnings released: US$0.52 loss per share (vs US$0.60 loss in 1Q 2023)

Full year 2023 earnings: EPS exceeds analyst expectations

Deciphera Pharmaceuticals, Inc. to Report Q4, 2023 Results on Feb 06, 2024

Third quarter 2023 earnings: EPS and revenues exceed analyst expectations

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

Deciphera Pharmaceuticals, Inc. to Report Q2, 2023 Results on Aug 09, 2023

Recent updates

Deciphera Pharmaceuticals, Inc. Files Form 15

Deciphera Pharmaceuticals, Inc.(NasdaqGS:DCPH) dropped from NASDAQ Composite Index

Deciphera Pharmaceuticals Announces Oral Presentation of Results from Motion Pivotal Phase 3 Study of Vimseltinib in Patients with Tenosynovial Giant Cell Tumor (Tgct) At the 2024 Asco Annual Meeting and Online Publication in the Lancet

First quarter 2024 earnings released: US$0.52 loss per share (vs US$0.60 loss in 1Q 2023)

Ono Pharmaceutical Co., Ltd. (TSE:4528) entered into a definitive merger agreement to acquire Deciphera Pharmaceuticals, Inc. (NasdaqGS:DCPH) for $2.2 billion.

Deciphera Pharmaceuticals, Inc.'s (NASDAQ:DCPH) 61% Share Price Surge Not Quite Adding Up

Ono Pharmaceutical Co., Ltd. (TSE:4528) entered into a definitive merger agreement to acquire Deciphera Pharmaceuticals, Inc. (NasdaqGS:DCPH) for $2.2 billion.

Price target increased by 7.1% to US$25.38

Deciphera Pharmaceuticals, Inc., Annual General Meeting, Jun 20, 2024

Diving Into Deciphera Pharmaceuticals

We Think Deciphera Pharmaceuticals (NASDAQ:DCPH) Can Afford To Drive Business Growth

Full year 2023 earnings: EPS exceeds analyst expectations

Consensus estimates of losses per share improve by 12%

Deciphera Pharmaceuticals, Inc. to Report Q4, 2023 Results on Feb 06, 2024

Deciphera Pharmaceuticals, Inc. Provides Earnings Guidance for the Fourth Quarter and Full Year Ended December 31, 2023

Deciphera Pharmaceuticals Announces Nature Medicine Publication of Results from Exploratory ctDNA Analysis from INTRIGUE Phase 3 Study Demonstrating Substantial Clinical Benefit of QINLOCK® in 2L GIST Patients with Mutations in KIT Exon 11 and 17/18

President recently sold US$471k worth of stock

Senior VP & Chief Commercial Officer recently sold US$224k worth of stock

We Think Deciphera Pharmaceuticals (NASDAQ:DCPH) Can Afford To Drive Business Growth

President recently sold US$259k worth of stock

Price target increased by 11% to US$24.44

Deciphera Pharmaceuticals, Inc. Announces Positive Top-Line Results from Motion Pivotal Phase 3 Study of Vimseltinib in Patients with Tenosynovial Giant Cell Tumor

Third quarter 2023 earnings: EPS and revenues exceed analyst expectations

Are Investors Undervaluing Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH) By 41%?

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

Deciphera Pharmaceuticals, Inc. Announces Board Changes, Effective from September 5, 2023

Deciphera Pharmaceuticals, Inc. to Report Q2, 2023 Results on Aug 09, 2023

Deciphera Pharmaceuticals (NASDAQ:DCPH) Is In A Good Position To Deliver On Growth Plans

Calculating The Intrinsic Value Of Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH)

Deciphera Pharmaceuticals, Inc. to Present Data from INTRIGUE Phase 3 Study of QINLOCK (ripretinib) and Trial-In-Progress Poster for Insights Pivotal Phase 3 Study of QINlock (Rpretinib) at the 2023 American Society of Clinical Oncology Annual Meeting

Independent Director recently bought US$152k worth of stock

Lacklustre Performance Is Driving Deciphera Pharmaceuticals, Inc.'s (NASDAQ:DCPH) Low P/S

First quarter 2023 earnings: EPS and revenues miss analyst expectations

We Think Deciphera Pharmaceuticals (NASDAQ:DCPH) Can Afford To Drive Business Growth

President notifies of intention to sell stock

Full year 2022 earnings: EPS exceeds analyst expectations

Deciphera Pharmaceuticals, Inc. to Report Q4, 2022 Results on Feb 07, 2023

Deciphera Pharmaceuticals, Inc. Presents Results from ctDNA Analysis of INTRIGUE Phase 3 Clinical Study at the American Society of Clinical Oncology Plenary Series Session

Executive VP recently sold US$51k worth of stock

Now 20% undervalued

Price target increased to US$21.10

Deciphera Pharmaceuticals, Inc. Provides Preliminary Unaudited Revenue Guidance for the Fourth Quarter and Full Year 2022

Price target increased to US$20.25

Deciphera Pharmaceuticals, Inc. Pharmaceuticals Announces Results from ctDNA Analysis from INTRIGUE Phase 3 Clinical Study Demonstrating Substantial Clinical Benefit of QINLOCK in Second-Line GIST Patients with Mutations in KIT Exon 11 and 17/18 Only

We Think Deciphera Pharmaceuticals (NASDAQ:DCPH) Can Afford To Drive Business Growth

Insufficient new directors

Third quarter 2022 earnings: EPS and revenues exceed analyst expectations

Deciphera Pharmaceuticals, Inc. to Report Q3, 2022 Results on Nov 03, 2022

Deciphera Pharmaceuticals, Inc. Presents Updated Phase 1/2 Data for Vimseltinib in TGCT at the European Society for Medical Oncology (ESMO) Congress 2022

Deciphera Pharmaceuticals, Inc. Presents Initial Phase 1 Single Agent Dose Escalation Data for First-in-Class ULK Inhibitor of Autophagy, DCC-3116, at the European Society for Medical Oncology (ESMO) Congress 2022

Deciphera initiated at buy at Cowen on Qinlock growth, pipeline; sees 68% upside

Deciphera Pharmaceuticals, Inc. Announces Publication of Intrigue Phase 3 Clinical Study Results in Journal of Clinical Oncology

Second quarter 2022 earnings: EPS and revenues exceed analyst expectations

Deciphera Pharmaceuticals Q2 2022 Earnings Preview

Deciphera Pharmaceuticals, Inc. to Report Q2, 2022 Results on Aug 04, 2022

We Think Deciphera Pharmaceuticals (NASDAQ:DCPH) Needs To Drive Business Growth Carefully

Deciphera Pharmaceuticals, Inc. Appoints Kelley Dealhoy as Senior Vice President and Chief Business Officer

First quarter 2022 earnings: EPS and revenues exceed analyst expectations

Deciphera Pharmaceuticals, Inc. to Report Q1, 2022 Results on May 04, 2022

Insufficient new directors

Deciphera Pharmaceuticals, Inc Presents Preclinical Data from DCC-3116 Program At the AACR Annual Meeting

Insufficient new directors

Deciphera Pharmaceuticals: Not Too Happy With The Risk-Reward Right Now

Deciphera Pharmaceuticals, Inc. to Report Q4, 2021 Results on Feb 08, 2022

Deciphera Pharmaceuticals, Inc. Presents Results from the INTRIGUE Phase 3 Clinical Study at the American Society of Clinical Oncology Plenary Series Session

Deciphera Announces Approval of QINLOCK® in the United Kingdom for the Treatment of Fourth-Line Gastrointestinal Stromal Tumor

Deciphera Pharmaceuticals, Inc. Receives European Commission Approval of QINLOCK® for Treatment of Fourth-Line Gastrointestinal Stromal Tumor

Deciphera Pharmaceuticals: The 75% Haircut Doesn't Seem Justified

Price target decreased to US$59.27